SEARCH

SEARCH BY CITATION

References

  • 1
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556562.
  • 2
    Spaulding A, Greene C, Davidson K, Schneidermann M, Rich J. Hepatitis C in state correctional facilities. Prev Med 1999; 28:92100.
  • 3
    Alter MJ, Hadler SC, Judson FN, Mares A, Alexander WJ, Hu PY, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990; 264:22312235.
  • 4
    Sànchez-Tapias JM, Barrera JM, Costa J, Ercilla MG, Pares A, Comalrrena L, et al. Hepatitis C virus infection in patients with nonalcoholic chronic liver disease. Ann Intern Med 1990; 112:921924.
  • 5
    Meyer RA, Gordon SC. Epidemiology of hepatitis C virus infection in a suburban Detroit community. Am J Gastroenterol 1991; 86:12241226.
  • 6
    Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997; 1:559568.
  • 7
    Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. New Engl J Med 1992; 327:19061911.
  • 8
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. New Engl J Med 1999; 340:745750.
  • 9
    Brown K, Crofts N. Health care costs of a continuing epidemic of hepatitis C virus infection among injecting drug users. Aust N Z J Public Health 1998; 22:384388.
  • 10
    Primary Liver Disease of Liver Transplant Recipients 1991 and 1992 (From the UNOS Scientific Registry). UNOS Update 1993; 9:27.
  • 11
    Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C. Ann Int Med 1997; 127:855865.
  • 12
    Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. New Engl J Med 1995; 332:14631466.
  • 13
    Belle SH, Beringer KC, Detre KM. Recent findings concerning liver transplantation in the United States. In: TerasakiPI, CeckaJM, eds. Clinical Transplants. Los Angeles, CA: UCLA Tissue Typing Laboratory, 1996: 1530.
  • 14
    Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823830.
  • 15
    The Veterans Affairs Cooperative Variceal Sclerotherapy Group. Sclerotherapy for male alcoholic cirrhotic patients who have bled from esophageal varices: Results of a randomized, multicenter clinical trial. Hepatology 1994; 20:618625.
  • 16
    Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47(RR-19):154.
  • 17
    Viladomiu L, Genescà J, Esteban JI, Allende H, Gonzalez A, Lopez-Talavera JC, et al: Interferon-alpha in acute post-transfusion hepatitis C: A randomized controlled trial. Hepatology 1992; 15:767769.
  • 18
    Lampertico P, Rumi M, Romeo R, Craxi A, Soffredini R, Biassoni D, et al. A multicenter randomized controlled trial of recombinant interferon alpha-2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994; 19:1922.
  • 19
    Hwang SJ, Lee SC, Chan CY, Lu RH, Lo KJ. A randomized controlled trial of recombinant interferon 2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994; 21:861866.
  • 20
    Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21:639644.
  • 21
    Takano S, Satomura Y, Omata M, Japan Acute Hepatitis Cooperative Study Group. Effect of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled dose study. Gastroenterology 1994; 107:805811.
  • 22
    Serfaty L, Nousbaum JB, Elghouzzi MH, Giral P, Legendre C, Poupon R. Prevalence, severity, and risk factors of liver disease in blood donors positive in a second generation anti-hepatitis C virus screening test. Hepatology 1995; 21:725729.
  • 23
    Inglesby TV, Rai R, Astemborski J, Gruskin L, Nelson KE, Vlahov D, et al. A prospective community based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999; 29:590599.
  • 24
    Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: Patients with normal aminotransferase levels and chronic hepatitis. Hepatology 1997; 26(suppl 1):133S136S.
  • 25
    Tassopoulos NC. Treatment of patients with chronic hepatitis C and normal ALT levels. J Hepatol 1999; 31(suppl 1):193196.
  • 26
    Mathurin P, Moussalli1 J, Cadranelet J-F, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology. 1998; 27:868872.
  • 27
    NHANES III (National Health and Nutrition Examination Survey, 1988-1994). Department of Health and Human Services, National Center for Health Statistics (NCHS). Document No. PB97-502959INC, National Technical Information Service, Springfield, VA.
  • 28
    Salmeron FJ, Palacios A, Perez-Ruiz M, Torres C, Oyonarte S, Fernandez-Montoya A, et al. Epidemiology, serological markers, and hepatic disease of anti-HCV ELISA-2-positive blood donors. Dig Dis Sci 1996; 41:19331938.
  • 29
    Alonso C, Pedrosa ML, de Sanjose S, Montcharmont P, Chevre JM, Boucaud MJ, et al. Hepatitis C virus among blood donors: Follow-up study. Transfusion 1994; 34:527530.
  • 30
    Gretch D, Lee W, Corey L. Use of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection in a diagnostic virology laboratory. J Clin Microbiol 1992; 30:21452149.
  • 31
    Fried MW, Shiffman ML, Reddy R, Smith C, Marino G, Goncales F, et al. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C. N Engl J Med 2002; 347:975982.
  • 32
    Manns MP, McHutchison JG, Gordon S, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358:958965.
  • 33
    Muir AJ, Provenzale D. An evaluation of eligibility for therapy among veterans with hepatitis C virus infection. J Clin Gastroenterol 2002; 34:268271.
  • 34
    Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997; 350:14251431.
  • 35
    Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. The Multivirc Group. Gastroenterology 1999; 116:378386.
  • 36
    Poynard T, McHutchinson J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon and ribavirin on the liver fibrosis progression in patients with chronic hepatitis C. Hepatology 2000; 32:11311137.
  • 37
    Long A, Spurll G, Demoers H, Goldman M. Targeted hepatitis C lookback: Quebec, Canada. Transfusion 1999; 29:194200.
  • 38
    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality and costs in the United States. Am J Public Health 2000; 20:15621569.
  • 39
    Bennett WG, Pauker SG, Davis GL, Wong JB. Modeling therapeutic benefit in the midst of uncertainty: Therapy for hepatitis C. Dig Dis Sci 1996; 41(12 Suppl):56S62S.
  • 40
    Davis GL, Beck JR, Farrell G, Poynard T. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: A decision analysis. J Viral Hepatol 1998; 5:313321.
  • 41
    Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol 2000; 95:15241530.
  • 42
    Joe GW, Lehman W, Simpson DD. Addict death rates during a four-year post-treatment follow-up. Am J Public Health 1982; 72:703709.